1

Positive attribute framing increases COVID-19 booster vaccine intention for

unfamiliar vaccines.

Barnes, K. PhD[1], Colagiuri, B. PhD[1]

[1] *University of Sydney, Australia*

Corresponding Author:

Dr. Kirsten Barnes,

School of Psychology, A18

University of Sydney

NSW 2006

Australia

Email: kirsten.barnes@sydney.edu.au

Abstract

Positive framing has been proposed as a potential intervention to increase COVID-19

vaccination intentions. However, most available research has examined fictitious or

unfamiliar treatments. This pre-registered study compared positively and negatively attribute-

framed side effect information for real COVID-19 booster vaccines (AstraZeneca, Pfizer,

Moderna) and measured intentions pre- and post-intervention in 1,222 UK-based participants.

Positive framing increased booster intentions among those with low baseline intentions

overall. As hypothesized, however, vaccine familiarity significantly modulated this effect,

with positive framing being effective for the least familiar vaccine (i.e., Moderna), while

standard negative framing appeared to increase intentions for familiar vaccines

(AstraZeneca/Pfizer). These findings provide important new evidence that positive framing

could improve vaccine uptake globally when switches or new developments require

individuals to receive less familiar vaccines – as is currently the case for millions of booster

vaccines across the world. Positive framing of familiar vaccines, however, should be treated

with caution.

Introduction

With vaccine efficacy for Severe Acute Respiratory Syndrome Coronavirus 2

(COVID-19) waning over time[1,2] and reduced for emerging variants[3,4], many countries are

currently accelerating their COVID-19 booster programmes[5,6] to protect against COVID-19

viruses[7,8]. However, vaccine availability does not necessarily translate to vaccine

acceptance[9], with the World Health Organization (WHO) recognising vaccine hesitancy as a

global health threat[10]. Side effect apprehension is a primary factor driving this hesitancy[11],

with one study finding 90% of COVID-19 vaccine refusers feared side effects more than the

virus itself[12]. Given the recency of booster programmes, evidence for hesitancy among those

already vaccinated is sparse. However, side effect severity associated with previous vaccine

doses has already been associated with booster hesitancy in one study[13]. Reducing

perceptions of negative side effects could be vital for increasing booster acceptance and

thereby reducing the global burden of the current COVID-19 pandemic.

One method of reducing negative perceptions regarding side effects, suggested by the

WHO[14], concerns "message framing" of vaccine-relevant information[15]. Positive attribute

framing, where side effect information is framed in terms of the inverse incidence rate (e.g.,

"60% will ***not*** get a sore arm") as opposed to typical negative framing with the standard

incidence rate (e.g., "40% will get a sore arm") could be particularly useful for combatting

COVID-19 vaccine hesitancy. First, it is directly applicable to side effects. Second, informed

consent is maintained as a consequence of statistical consistency across frames[16]. Third, there

is preliminary evidence that positive attribute framing can improve vaccination attitudes in

other settings. For example, one study on the influenza vaccine found positive attribute

framing (hereafter positive framing) reduced the expectation and experience of side effects,

increased perceived protection from influenza, and reduced distortions in the perception of

side effect risk[17], with this pattern of results replicated for other vaccine types[18].

Studies examining whether COVID-19 vaccine intention is amenable to framing

techniques have produced mixed results[19-21]. However, these studies focused on vaccine-

naïve individuals, did not employ attribute framing, and did not concern booster intentions.

Critically, existing studies either used fictitious COVID-19 vaccines[19,20] or did not name

specific COVID-19 vaccines that at the time were being approved for administration[21]. As

such, participants either had limited knowledge of, or investment in, the framed vaccines. As

the pandemic has progressed, media discourse[22,23] combined with direct and socially-

observed experience of COVID-19 side effects[24], means it is essential to understand whether

positive framing is effective for real-world vaccines where prior knowledge and experience

exists.

This is particularly important because there is reason to believe that prior knowledge

regarding a given COVID-19 vaccine may moderate the strength of any positive framing

effect. For example, the increased relevance of, or belief in, a particular treatment or societal

issue has been shown to decrease the efficacy of different forms of framing[25,26], including the

effect of positive framing on the perception of hypothetical vaccines[25,27]. The effect of

positive framing on vaccine intention may therefore be limited to less familiar vaccine types.

However, there are two important reasons why attribute framing may still hold utility for

COVID-19 vaccines even if limited to unfamiliar vaccines. First, new composition changes to

COVID-19 booster vaccines have been recommended[28] and are currently being developed[29]

to protect against emerging variants. Second, many booster programmes (e.g., in the United

Kingdom) require individuals to switch from their previous COVID-19 vaccine (e.g.,

AstraZeneca Vaxzevria). Some alternatives (e.g., Pfizer Cominarty) are more familiar than others (e.g., Moderna Spikevax). As treatment switches have been demonstrated to result in poorer health outcomes and treatment discontinuation in general[30,31], positive framing may be beneficial for increasing uptake for booster switches of this type. However, as medical research on positive framing has tended to focus on fictitious medications and patient scenarios[25,27,32-36], a paucity of evidence exists concerning the effect of familiarity on ecologically valid treatments, especially given the salience of COVID-19 vaccinations at the population level.

In this pre-registered study (aspredicted.org/53ph4.pdf), conducted in the UK, attribute framing was applied to side effects from genuine manufacturer Patient Information Leaflets (PILs) for the AstraZeneca, Pfizer, and Moderna vaccines. A factorial design was employed, with participants randomised to read positive or negatively framed PILs for the same vaccine they had previously received (either AstraZeneca/Pfizer), a familiar vaccine in the UK context (Pfizer/AstraZeneca), or an unfamiliar vaccine (Moderna). It was hypothesised that a) positive framing would increase booster intention, and b) the effect of positive framing would decrease with vaccine familiarity. Following previous research[16,32,37-39] secondary outcome variables concerning booster side effect severity, perceived risk, and booster acceptance (satisfaction, happiness, anxiety) were explored as potential mediators of the framing effect on vaccine intention.

Results

Overview

Participants (*N*=1,222) were recruited via Pureprofile, an international recruitment service, between 27th October and 8th November 2021. All were pre-screened (see Methods)

with data removed based on pre-registered quality control criteria (see Supplementary

Materials 1). Only those who had received two doses of either the AstraZeneca or Pfizer

COVID-19 vaccines were eligible to participate, with participants stratified by their previous

vaccine type.

Participants from each stratum were subsequently randomised to one of six

experimental conditions (3(Familiarity) * 2(Framing) factorial design; see Figure 1). Baseline

ratings were collected regarding primary and secondary outcome measures—all recorded on

a 100-point VAS. The primary outcome was the participant's intention to receive a booster

vaccine. Secondary outcomes were: 1) perceived booster side effect severity; 2) perceived

booster risk; 3) booster acceptance (with satisfaction, happiness, and anxiety measured

separately). Wording of items can be found in Figure 1. Familiarity with the side effects of

the AstraZeneca, Pfizer, and Moderna vaccines were additionally assessed (100-point VAS)

to determine whether side effect knowledge corresponded with the predetermined factorial

categories of vaccine Familiarity (i.e., Same > Familiar > Unfamiliar).

Figure 1: Sample size, experimental design, and item wording for primary and secondary

outcomes

Framed side effect information was subsequently presented dependent on condition.

This information took the form of genuine manufacturer PILs for the AstraZeneca, Pfizer,

and Moderna vaccines. Side effects were retained in their original form and order and

presented in standard EU verbal prevalence categories and frequency bands. Positive framing

was applied only to the frequency bands (for example see Figure 2, with full wording and

PILs presented as Supplementary Materials 2-3). To manipulate familiarity, participants were

randomised to view PILs from the following conditions: 'Same' (PIL for the COVID-19

vaccine previously received: AstraZeneca-AstraZeneca|Pfizer-Pfizer); 'Familiar' (PIL for a

common vaccine not previously received: Pfizer-AstraZeneca|AstraZeneca-Pfizer);

'Unfamiliar' (PIL for a less common vaccine in the UK: AstraZeneca-Moderna|Pfizer-

Moderna). Familiarity was judged based on UK data (22nd September 2021) outlining that

19.4 and 24.0 million second doses of the Pifzer and AstraZeneca vaccines had been

delivered respectively, relative to 1.2 million of Moderna[40]. After timed PIL presentation of 2

minutes, all participants provided post-manipulation ratings for the primary and secondary

outcomes (as above). Participants were then presented with 14 side effects from the PIL they

had read and were required to: 1) assign each to a verbal prevalence category (i.e., very

common, common, uncommon, rare, very rare); 2) estimate frequency of occurrence (number

of people in 100,000 expected to experience the side effect.

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)
Common (may affect up to 1 in 10 people)	**Common** (90 in 100 or more people may **_not be affected_**)	**Common:** 90 in 100 (blue circles) or more **not affected**
Uncommon (may affect up to 1 in 100 people)	**Uncommon** (990 in 1,000 or more people may **_not be affected_**)	**Uncommon:** 990 in 1,000 (blue circles) or more **not affected**

Figure 2: Positive and negative wording used to frame common and uncommon side effects

(wording for all prevalence categories can be found in Supplementary Materials 2)

Descriptive Statistics

Sample Demographics

Information regarding participant location, age, education, and employment can be found

in Figure 2a-b. Participants were 52.5 years of age on average (range=18-95). As presented in

Figure 2a, they resided across most postal areas in the UK, with the largest proportion from

London district (*N*= 53), Birmingham (*N*=35), and Belfast (*N*=34). Only Harrogate, and the

Orkney and Shetland Islands were not represented. Most respondents identified as British

(*N*=1,064; 87%). Those self-reporting as female were represented slightly more frequently than

other genders (*N*=706; 58%), 34% of the sample had completed undergraduate-level education

(*N*=413), and 33% were in full-time employment (*N*=407). Full descriptive statistics for the full

sample, and by condition, are presented as Supplementary Materials (4-5).

COVID-19 Exposure and Vaccine History

Most participants (*N*=1,074; 88%) had not personally been infected with COVID-19,

while 565 (46%) reported infections among family and close friends. On average, participants

had their last COVID-19 vaccine 4.8 months ago. The largest proportion reported not

experiencing side effects to either dose (*N*=579; 47%). Of those who did, the first dose was most

associated with severe side effects (*N*=372; 30%).

Figure 3: Demographic Information, where 3a plots the frequency of participants from each postal area of the UK against the

vaccination rates reported by the UK government on the 3rd November (the final week of data collection) and 3b depicts education and

employment categories, and age range, across experimental conditions.

Primary Analysis

Knowledge of vaccine side effects mirrors categorical levels of the Familiarity factor

To determine whether side effect familiarity corresponded with the predetermined

factorial categories of Familiarity (i.e., Unfamiliar, Familiar, Same), a within-subjects one-way

ANOVA (with Greenhouse–Geisser correction) was run on side effect familiarity ratings

collected for the three vaccine types prior to the experimental manipulation. A robust main effect

of Familiarity was observed ($F(1.86, 2272.18)=659.17$, $p<.001$, $\eta_p^2=.35$). Awareness of side

effects increased with Familiarity; being higher for the Same vs. Familiar vaccine

($t(1221)=14.11$, $p<.001$, Cohen's $d_z=.40$), and for the Familiar vs. Unfamiliar vaccine

($t(1221)=23.97$, $p<.001$, Cohen's $d_z=.69$). Mean differences are presented in Figure 4e.

Baseline Intention to be vaccinated

A 2(Framing) * 3(Familiarity) ANOVA was conducted on Baseline Booster Intention

scores to assess the presence of between-group differences on this variable. Levels of Baseline

Booster Intention were anticipated to be high across all conditions (see pre-registration), which

was confirmed in the present sample ($M=78.36$ (/100-point VAS), $SD=31.65$; range:0-100).

However, an unanticipated significant effect of Familiarity was observed on Baseline Booster

Intention ($F(2, 1216)=49.51$, $p<.0001$, $\eta_p^2=.075$). This effect reached significance for the

orthogonal contrast comparing the Same vs. Other (i.e., combined Familiar and Unfamiliar)

vaccine types ($F(1, 1216)=96.51$, $p<.0001$, $\eta_p^2=.074$), but not for the Familiar vs. Unfamiliar

comparison ($F(1, 1216)=2.42$, $p=.120$, $\eta_p^2=.002$), indicating higher intentions for previously

experienced vaccines.

Effect of framing and familiarity on the intention to be vaccinated

The pre-registered primary analysis plan was a 2(Framing: Positive vs. Negative)*3

(Familiarity: Same Vaccine, Familiar Vaccine, Unfamiliar Vaccine) factorial ANCOVA, with

Baseline Booster Intention for the vaccine presented in the participant's assigned PIL as the

covariate, and Post-Manipulation Booster Intention the outcome. However, the fact that Baseline

Intention unexpectedly differed systematically with Familiarity meant that including it as a

covariate without including its interactions with the manipulated variables (Framing and

Familiarity) would violate the assumptions of ANCOVA[41]. Therefore, to address this, we

extended the model to include the interactions between Baseline Booster Intention and the

manipulated variables in all analyses, as has previously been recommended when differences in

the covariate exist[42]. Pre-specified orthogonal contrasts for Familiarity were: Contrast1 (Same

vs. Other [Familiar and Unfamiliar combined]); Contrast2 (Familiar vs. Unfamiliar). A

Framing*Familiarity interaction was hypothesised, with the effect of Framing (increased Booster

Intention following Positive vs. Negative framing) reducing with increased Familiarity.

Main effects analysis revealed the anticipated Framing*Familiarity interaction ($F(2,$

$1210)=10.75$, $p<.0001$, $\eta_p^2=.018$). Specifically, Framing interacted with Contrast1 (Same vs.

Other: $F(1, 1210)=5.07$, $p=.025$, $\eta_p^2=.004$) and Contrast2 (Familiar vs. Unfamiliar: $F(1,$

$1210)=16.46$, $p=.0001$, $\eta_p^2=.013$). As demonstrated in Figure 4a which depicts the interaction

means, this pattern of results was driven by Positive Framing increasing Booster Intention for the

Unfamiliar vaccine. However, this was superseded by a three-way interaction with Baseline

Booster Intention ($F(2, 1210)=7.65$, $p=.0005$, $\eta_p^2=.013$), represented at both Contrasts

(Baseline*Framing*Contrast1: $F(1, 1210)=4.39$, $p=.036$, $\eta_p^2=.004$ |

Baseline*Framing*Contrast2: $F(1, 1210)=11.19$, $p=.0008$, $\eta_p^2=.009$). Data presented in Figure

4b, that depicts this interaction, provides a more nuanced understanding of results. Viewing side

effect information of any type appeared to increase average Booster Intention (i.e., post-

manipulation model estimated means were above zero, for all levels of the baseline covariate).

Positive Framing had limited efficacy at high levels of Baseline Intention across Conditions but

took effect for the Unfamiliar Vaccine when model estimated VAS scores were lower than

~80/100. At very low levels of Baseline Intention (i.e., VAS=0), model predicted Booster

Intention Post-Manipulation increased from $M=19.09$ ($SEM=2.76$, 95% CIs[13.68, 24.50]) for

the Negative Frame, to $M=35.11$ ($SEM=2.77$, 95% CIs[29.68, 40.50]) for the Positive Frame.

Full model output is included as Supplementary Materials 6. We note that the same interaction

between Framing and Familiarity was observed in the planned but invalid model excluding the

interaction between these factors and Baseline Booster Intention (see Supplementary Materials

7).

The effect of positive framing on vaccine switches

Analyses were performed to investigate the effect of framing on pre-registered and

realistic vaccine switches occurring as part of the UK's booster programme. Specifically, those

without medical exemption, who previously received the AstraZeneca vaccine will be required to

switch to Pfizer or Moderna, while those who received Pfizer may be required to switch to

Moderna.

First, previous vaccine type (AstraZeneca/Pfizer) was entered as a factor in the

ANCOVA model above to check for interactions with Framing, Familiarity, and Baseline

Booster Intention. While there was a main effect of previous vaccine type ($F(1, 1198)=6.36$,

p=.012, $\eta_p{}^2$=.005), with those receiving AstraZeneca reporting increased Booster Intention

(*M*=80.83, *SEM*= 0.74, 95% CIs [79.37, 82.29]) compared to Pfizer (*M*=78.01, *SEM*= 0.74, 95%

CIs [76.57, 79.46]), there were no two- or three-way interactions with Framing or Familiarity (all

ps>.05; see Supplementary Materials 8).

248   ***Previous Vaccine: AstraZeneca***

249   Representative of a switch from AstraZeneca to Pfizer or Moderna, a

2(Framing)*2(Familiarity: Familiar (Pfizer), Unfamiliar (Moderna)) ANCOVA, with

interactions between the covariate (Baseline Booster Intention) and factors modelled, was

conducted among those who had previously received the AstraZeneca vaccine (*N*=410). A three-

way Framing*Familiarity*Baseline Intention interaction was observed (F(1, 402)=11.38,

p=.0008, $\eta_p{}^2$=.028). As demonstrated in Figure 4c, in the case of the Unfamiliar vaccine

(Moderna) Booster Intention was increased in the Positive Frame at low levels of Baseline

Booster Intention. However, the inverse of this pattern was observed for the Familiar vaccine

(Pfizer), where Positive Framing decreased Booster Intention at low levels of Baseline Intention.

259   ***Previous Vaccine: Pfizer***

260   Representative of a switch from Pfizer to Moderna, a one-way ANCOVA investigating

the effect of framing on the perception of the Unfamiliar (i.e., Moderna) PIL was performed on

the data of those who had previously received the Pfizer vaccine (*N*=202). There was a main

effect of Framing (*F*(1, 198)=3.98, *p*=.048, $\eta_p{}^2$=.020), but no statistically significant Baseline

Booster Intention*Framing interaction (*F*(1, 198)=1.80, *p*=.181, $\eta_p{}^2$=.009). However, as

demonstrated in Figure 4d, slopes for the Positive and Negative Frame converged at high levels

of Baseline Booster Intention.

Figure 4: Model estimated mean differences in the primary outcome (Booster Intention),

depicted for the whole sample (4a and 4b), and for realistic switches occurring as part of the UK

booster programme (4c and 4d). 4e presents data demonstrating that side effect familiarity

ratings scaled with the factorial levels of Vaccine Familiarity. All error bars represent ± 1SEM.

Secondary Analyses

Positive framing decreases the perception of booster side effect severity

Perceived side effect severity associated with the vaccines was measured pre- and post-

manipulation. A 2(Framing)*3(Familiarity) ANCOVA (contrasts as above), including

interactions with the covariate (Baseline Side Effect Severity), revealed a main effect of Framing

($F(1, 1210)=3.92$, $p=.048$, $\eta_p^2=.003$), and a Baseline Severity*Framing interaction ($F(1,$

$1210)=4.52$, $p=.034$, $\eta_p^2=.004$). There were no other two- or three-way interactions (all $ps>.35$).

As depicted in Figure 5a, reading about side effects in any frame increased the perception of

their severity (i.e., post-manipulation model estimated means are above zero, for all levels of the

baseline covariate). However, Positive Framing resulted in a lower perception of side effect

severity, which was strongest when side effects were perceived as severe at baseline. Full model

output is included as Supplementary Materials 8.

Perception of booster vaccine risk decreases with vaccine familiarity

Perception of risk to participant's health associated with receiving the vaccines was

recorded pre- and post-manipulation. The main effect of Framing did not reach statistical

significance ($F(1, 1210)=1.04$, $p=.308$, $\eta_p^2=.001$). There was a Familiarity*Baseline Risk

Perception interaction ($F(2, 1210)=4.82$, $p=.008$, $\eta_p^2=.008$), evident in both contrasts (Baseline

Risk*Contrast1: $F(1, 1210)=4.28$, $p=.039$, $\eta_p^2=.004$ | Baseline Risk*Contrast2: $F(1, 1210)=6.03$,

$p=.014$, $\eta_p^2=.005$). No other statistically significant main effects or interactions were observed

(all $ps>.10$). As depicted in Figure 5b, there was limited difference between Familiarity

conditions when the perception of risk was low at baseline. At high levels of Baseline Risk, Post-

Manipulation Risk Perception was lowest for the previously experienced vaccine and highest for

the Unfamiliar vaccine. Full model output is included as Supplementary Materials 10.

Positive framing increases satisfaction and happiness with the framed booster but does

not reduce anxiety

At pre- and post-manipulation, participants were asked to imagine that the framed

vaccine was their only option for a booster and to rate their Satisfaction, Happiness and Anxiety

regarding this outcome. In order to reduce the data for analysis, the three variables were entered

into a principal components analysis. Component loading suggested that Satisfaction and

Happiness loaded onto a similar latent construct, while Anxiety was associated with another.

Therefore, Satisfaction and Happiness were averaged together for the subsequent analyses, while

Anxiety was treated separately. Two ANCOVAs were run on these outcomes. The first revealed

a main effect of Framing ($F(1, 1210)=5.66$, $p=.018$, $\eta_p^2=.005$) and a Framing*Familiarity ($F(2,$

$1210)=3.63$, $p=.027$, $\eta_p^2=.006$) and Baseline Satisfaction/Happiness*Framing*Familiarity ($F(2,$

$1210)=3.43$, $p=.033$, $\eta_p^2=.006$) interaction. This three-way interaction was significant for

Contrast1 (Same vs. Other: $F(1, 1210)=4.11$, $p=.043$, $\eta_p^2=.003$), but not Contrast2 (Familiar vs.

Unfamiliar: $F(1, 1210)=2.56$, $p=.110$, $\eta_p^2=.002$). As shown in Figure 5c, for the Same and

Unfamiliar vaccines, lowered satisfaction and happiness were generally associated with Negative

Framing, particularly at low levels of Baseline Satisfaction/Happiness. There appeared to be no

difference for the Familiar vaccine.

With respect to anxiety, there was a significant Baseline Anxiety*Framing interaction

($F(1, 1210)=5.53$, $p=.019$, $\eta_p^2=.005$), but no other main effects or interactions (all $ps>.05$). As

shown in Figure 5d, Positive Framing appeared to increase Post-Manipulation Anxiety at very

high levels of Baseline Anxiety, but was limited to the Same Condition (i.e., among participants

who had high Baseline Anxiety regarding continuation with their previous vaccine type), with

this interaction nearing significance (Anxiety*Framing*Contrast1: $F(1, 1210)=3.65$, $p=.056$,

$\eta_p^2=.003$). Correlations, PCA, and Models are presented as Supplementary Materials 11.

Figure 5: Mean values for secondary outcome measures, where 5a depicts model-estimated mean

differences regarding side effect severity ratings, 5b perceptions of vaccine risk, 5c combined

satisfaction and happiness associated with the framed vaccine, and 5d anxiety surrounding the

framed vaccine. All error bars represent ± 1SEM.

Positive framing influences judgements regarding side effect prevalence

Participants were required to classify 14 side effects from their assigned PIL into verbal

prevalence categories, as well as provide a frequency estimate regarding how many people, in

100,000, they thought would experience each side effect if they received the framed vaccine.

Eleven side effects were associated with discrete prevalence categories. Three were presented in

the PILs as of 'unknown prevalence'. Raw frequency estimates of the latter were analysed

separately to test whether framing alters perceptions regarding prevalence when no information

is provided. Side effects from each PIL are included as Supplementary Materials 12. For side

effects with a concrete category, the percentage of side effects correctly assigned across verbal

prevalence categories, and frequency bands, were computed as outcome measures. Frequency

estimates were judged correct based on the following frequency bands[39]: Very Common =

10,001–100,000 (>10%); Common = 1001–10,000 (>1–10%); Uncommon = 101–1000 (>0.1–

1%); Rare = 11–100 (>0.01–0.1%); Very Rare = 0–10 (0–0.01%). ANOVAs were performed

with Framing and Familiarity as factors.

Verbal Prevalence Categories

As depicted in Figure 6a, a main effect of Framing ($F(1, 1216)=5.54$, $p=.019$, $\eta_p^2=.005$)

was observed, while Familiarity neared significance ($F(2, 1216)=2.98$, $p=.051$, $\eta_p^2=.005$). This

was driven by Contrast1 only (Same vs. Other: $F(1, 1216)=4.93$, $p=.027$, $\eta_p^2=.004$). While

accuracy was generally low, fewer accurate classifications were made following Positive

Framing ($M=30.9\%$, $SEM=0.73$, 95% CIs [29.46, 32.31]), relative to Negative Framing

($M=33.3\%$, $SEM=0.73$, 95% CIs [31.87, 43.73]). While the reduction in accuracy associated with

positive, relative to negative, framing appeared to decrease with familiarity, the

Framing*Contrast1(Same vs. Other) interaction did not reach statistical significance (F(1,

1216)=3.11, p=.078, η_p^2=.003). Full model output is included as Supplementary Materials 13.

Frequency Estimates

A main effect of Framing (F(1, 1216)=6.45, p=.011, η_p^2=.005) and Familiarity (F(2,

1216)=9.71, p=.0001, η_p^2=.016) was observed. As depicted in Figure 6b, accuracy was reduced

with Positive Framing, but increased with Familiarity. Contrast1 (Same vs. Other: F(1,

1216)=9.52, p=.002, η_p^2=.008) and Contrast2 (Familiar vs. Unfamiliar: F(1, 1216)=9.84, p=.002,

η_p^2=.008) reached significance. Overall, participants frequency estimates were less accurate

following positive framing (*M*=20.7%, *SEM*=0.74, 95% CIs [19.40, 22.32]) relative to negative

framing (*M*=23.54%, *SEM*=0.74, 95% CIs [22.08, 25.00]). Framing did not interact with the

main effect of Familiarity, or the orthogonal contrasts (all *ps*>.30). Full model output is included

as Supplementary Materials 14.

Neither Framing nor Familiarity had any effect on frequency estimates of side effects of

'unknown' frequency (all *ps*>.16; see Supplementary Materials 15). Those in the Positive

Framing conditions estimated that these side effects would be experienced by 1,848/100,000

people on average, and those in the Negative Frame as 2,004/100,000.

Figure 6: Mean percentage of correct category (6a) and frequency (6b) judgements. All error

bars represent ± 1SEM.

Discussion

Message framing has been suggested as a potential intervention to increase COVID-19

vaccine uptake[14]. In the present study, positive and negative attribute framing was applied to

genuine side effect information from manufacturer PILs for three COVID-19 vaccines

(AstraZeneca, Pfizer, Moderna). Booster intention was measured pre- and post-manipulation.

Primary analysis revealed that positive framing successfully increased the intention to be

vaccinated for unfamiliar vaccines (i.e., Moderna), but appeared to reduce booster intention for

the vaccine that had previously been received, as well as for a switch to the Pfizer vaccine among

those previously receiving AstraZeneca. In all cases, effects were strongest when baseline

booster intentions were low. Increasing booster acceptance among those with low intentions is of

substantial importance in protecting against infection from, and transmission of, COVID-19

viruses. Our data suggest that any intervention that intends to employ attribute framing should be

carefully tailored to match the framed information (i.e., positive vs. negative wording) with

vaccine familiarity. Specifically, positive framing appears to have significant potential when the

vaccine is unfamiliar, such as in situations such when a novel vaccine is being introduced or

there are composition changes to the vaccine[28,29]. By contrast, our data also suggest that positive

framing may actually be harmful when the vaccine is familiar.

The significant effect of positive attribute framing on booster intentions for the

Unfamiliar vaccine is consistent with research concerning medical decision making. In those

studies, framed information has typically been presented regarding fictitious medications and

patient scenarios[25,27,32-36]. In other cases using real treatments, data has been collected from

samples where participants were either completely[17,43] or largely[44] naïve to the framed treatment,

or where prior treatment experience was not assessed[18,45]. The current data thereby provide new

insights into the effect of framing. Under conditions directly relevant to the COVID-19 pandemic

(i.e., for real vaccines, at high levels of public involvement), the benefit of positive attribute

framing was found to wane, or in some instances to be reversed, as familiarity and prior

experience with the framed vaccine increased. As such, calls for all PILs to employ positive

framing as standard (e.g.,[32,46]) appear premature. Positive framing appears beneficial only for

unfamiliar vaccines whereas negative framing, the standard form for communicating side effect

information within the European Union, appears beneficial when treatments are well known.

The reduced efficacy of positive framing observed as vaccine familiarity increased could

be explained by a current theory of attribute framing that posits an interaction between

familiarity (a specific manifestation of psychological distance) and the valence of the message

surrounding a given attribute or event (e.g., the experience of vaccine side effects). At closer

psychological distances (e.g., for vaccines that are more familiar and more likely to be received),

negatively framed information has been shown to be more persuasive[47]. Further experimental

research is needed to test this theory, while also considering alternative explanations, such as the

role of potential backfire effects in persuasive or corrective messaging that are known to impact

attitudes surrounding the COVID-19 pandemic[48] and have been demonstrated to lower intentions

for other vaccine types at high levels of concern[49]. However, when assessed in conjunction,

results presented here highlight the fact that any intervention that strives to apply positive

framing across all vaccine types irrespective of familiarity should be treated with caution.

421   Perceived booster side effect severity, perceived booster risk, and booster acceptance

(satisfaction, happiness, and anxiety) were examined as secondary variables to explore potential

mediators of the effect of positive framing on booster intention. None of the patterns of these

secondary variables mirrored the results obtained for the primary outcome – booster intention.

Instead, positive framing appeared to have a more general capacity to increase favourable

perceptions of the COVID-19 vaccines, decreasing perceptions of side effect severity, and

increasing satisfaction and happiness in some instances. These results may appear difficult to

reconcile with the observed changes in vaccine intention. However, post-hoc analysis (see

Supplementary Materials 15) plotting the Familiarity*Framing*Baseline interaction on side

effect severity and booster acceptance for those who had high vs. low baseline booster intent,

suggests that framing-induced changes on these secondary variables largely occurred among

those with high vaccine intention at baseline. Notably, participants with high baseline booster

intentions showed limited effect of framing on their behavioural intention to be vaccinated. Thus,

rather than being inconsistent with the primary outcome data, this exploratory pattern of results

simply suggests that changes in booster intention with framing are unlikely to driven by changes

in the perception of the COVID-19 vaccines as measured here. Investigation of other factors

combined with qualitative research may be better positioned to identify the driving factors

behind changes in booster intention that occur with the framing of COVID-19 vaccinations.

Estimates of side effect prevalence were found to be quite poor (<~35% accuracy) after

reading the information contained in the PILs, irrespective of frame. This is consistent with

previous research[39,50-53] and highlights limitations with the current format of communicating side

effect information. It was interesting to note that an additional reduction in accuracy was also

observed for the positive frame, which did not interact with familiarity. However, patterns within

the data were inconsistent, with reduced accuracy associated with the Unfamiliar vaccine

appearing exacerbated for verbal prevalence categories but ameliorated for frequency estimates.

As such, it is unclear whether positive framing has the potential to undermine informed consent[16]

by reducing accuracy concerning side effect prevalence. Further, because the present study

employed genuine PILs, the side effects participants were required to judge differed across

vaccine types. As such, the study was designed only to test for general inaccuracies in side effect

representation and not systematic over- or under-estimation. Experimental studies are therefore

needed to assess precisely how any inaccuracies associated with positively framed COVID-19

vaccine information manifest.

The primary strength of the present study is the application of attribute framing to real

COVID-19 vaccines with real PILs. The PILs employed here are displayed on government and

NHS websites in the UK, forming a primary official source of information regarding COVID-19

vaccination. Our findings therefore have real-world implications, demonstrating that the wording

of PILs can directly impact the intention to receive a booster vaccine among individuals for

whom this decision is both directly relevant and imminent. There are of course some limitations

worth noting including the collection of cross-sectional data that limits an assessment of the

durability of the framing effect, as well as a sample located within a single country. Given global

differences in booster policy, cross-cultural replication of results is required to ensure that the

data presented here is not contextually limited to the UK. While vaccine intention has been

demonstrated to be a strong predictor of vaccine uptake[e.g.,[54-56]], including for COVID-19

vaccination[57], we do not assume that the two are synonymous[58]. While beyond the scope of the

present study, we recommend that future research incorporate longitudinal designs where the rate

of conversion from intention to vaccine uptake can be tracked. Further, the results presented here

are specific to booster intentions among those already vaccinated. While side effect apprehension

has been associated with hesitancy regarding COVID-19 vaccination[11] and booster vaccination[13],

whether a similar pattern of results would hold among those who have never been vaccinated is

unknown.

In summary, the present study demonstrates that the ability of positive framing to

successfully increase booster intention for genuine COVID-19 vaccines is critically moderated

by the familiarity of that vaccine. Positive framing can improve vaccine intention for unfamiliar

vaccines, but may actually decrease intentions for familiar vaccines. The data therefore provide

novel insights into the benefits of positive framing for COVID-19 vaccines and beyond. As such,

we recommend that if positive attribute framing is to be employed, close attention must be paid

to the type of treatment being framed as well as the likely recipients of the framed information.

Importantly, in the context of the current COVID-19 pandemic, positive framing appears capable

of improving uptake of COVID-19 vaccines when switches or new developments require

individuals to receive unfamiliar vaccines, as is the case for many booster vaccine programmes

globally, but should be treated with caution for familiar vaccines.

486   **Methods**

Recruitment and Sample

Recruitment took place in the initial weeks of the UK booster programme (27th October - 8th

November 2021). Figure 3a provides a summary of the number of boosters administered in the

UK at the time of data collection. The sample was obtained from Pureprofile, an ISO-certified

panel provider for online research, and balanced on national quotas for age, gender, and region.

All potential participants were screened using the following inclusion criteria: 18 years of age or

older, currently residing in the UK, self-reported English fluency, previously received two doses

of either the Pfizer or the AstraZeneca COVID-19 vaccines (no other combination), not having

received a third COVID-19 booster vaccine, and no known medical reason (e.g., allergy)

prohibiting potential administration of the Pfizer, AstraZeneca, or Moderna COVID-19 vaccines.

After screening, 1896 participants provided electronic consent and 1459 completed the

experiment. To reduce statistical noise due to random and inconsistent responding, 237

completing participants were removed based on pre-registered quality control criteria (see

Supplementary Materials). The experiment was approved by the University of Sydney Human

Research Ethics Committee. All completing participants were provided with an electronic

debrief at the end of the survey and were paid £3.50 for a ~15-minute survey.

Data Collection and Procedure

Cross-sectional data were collected online via Qualtrics, with the survey accessible to

personal computer, tablet, and smartphone. The 'force response' option was used to ensure

complete cases for all outcome variables. Participants completed the survey in one sitting and

were not able to return to the study URL. After pre-screening, those meeting the inclusion

criteria were provided with a participant information statement detailing the aims of the study

and gave their digital informed consent. Those not meeting these criteria were directed away

from the survey.

Participants completed demographic items and identified which COVID-19 vaccine they

had previously received (AstraZeneca or Pfizer). Stratified randomisation to the six experimental

groups occurred at this point using the inbuilt Qualtrics randomisation function. Quotas were set

to limit data collection to 600 participants from each vaccine type (AstraZeneca/Pfizer), with 100

from each group randomised to the six experimental conditions. Because Qualtrics tallies quotas

on survey completion but does not account for participants currently in the experimental

pipeline, the final sample contained 22 more participants than projected. Statistical analysis did

not take place until after exclusions had been made and all quotas were closed.

After randomisation, participants responded to items concerning the number of months

since their last COVID-19 vaccine and familiarity with side effects of the three framed vaccines.

For each vaccine type, participants then rated their booster intention, perceived booster side

effect severity, perceived booster risk, and booster acceptance (satisfaction, happiness, and

anxiety). Responses made to the vaccine type that matched with the experimental condition to

which the participant had been assigned were employed as baseline measures. Responses to all

other vaccine types were recorded for use in a concurrent, but separate, pre-registered study

(#78370; aspredicted.org/8e6af.pdf). PILs containing the positively or negatively framed side

effect information were then displayed for two minutes, using a timer embedded in the survey.

Participants could not proceed until this time had elapsed. Post-manipulation booster intention,

perceived booster side effect severity, perceived booster risk, and booster acceptance were then

recorded. Finally, fourteen side effects described in the PILs were presented, with participants

required to assign each to a verbal prevalence descriptor (very common, common, uncommon,

rare, very rare) and estimate how many people (out of 100,000) taking the vaccine would

experience the side effect. On completing the survey, all participants were provided with an

electronic debrief for download and URLs to the UK government landing page where the

original PILs for the vaccines used in the study could be found.

Several additional items concerning general COVID-19 booster intentions, perceived risk

of previous COVID-19 vaccines, specific COVD-19 vaccination side effects, general perceptions

of COVID-19 and COVID-19 vaccinations, and severity of previous COVID-19 infection, were

included in the survey for use in a separate pre-registered study (#78370;

aspredicted.org/8e6af.pdf), but are not analysed or reported on here.

Survey Materials

546    *Demographic Information*

547    Participants responded to items concerning their age, gender, ethnicity, highest level of

548 education and employment status, and geographic region (postal area code). Exact wording can

549 be found in the Demographic Information section, Supplementary Materials 4.

551    *Previous exposure to COVID-19*

552    Items were employed to capture personal exposure to COVID-19, as well as exposure

553 through close friends and family. Item wording (*To your knowledge, are you, or have you been,*

554 *infected with COVID-19? / To your knowledge, have any of your close family members or friends*

555 *been infected with COVID-19?)* was taken from the WHO BeSD documentation[14].

557    *Previous COVID-19 Vaccination History*

558    Previous COVID-19 vaccine (Pfizer/AstraZeneca) was recorded as a forced-choice

559 option. Participants indicated the number of months since their last COVID-19 vaccine, and

560 whether their most severe side effects occurred to their first dose, second dose, whether they

561 were equal across doses, or not experienced at all.

563    *Familiarity with COVID-19 vaccine side effects*

For the three framed vaccines, participants were asked to rate their "*familiarity with the*

potential side effects" on a 100-point VAS, with anchor labels (*'not at all familiar'* / *'extremely*

familiar') positioned to the left and right of the scale. Those who had not heard of the vaccine

were asked to check a separate '*not heard of vaccine'* box but received a score of zero (*not at all*

familiar). This response-type was used to exclude inconsistent responders (see Supplementary

Materials 1).

Baseline Measures: COVID-19 Vaccine Perceptions

Four items were used as baseline measures. All were rated on a 100-point VAS. For each

of the three vaccines, participants responded to questions concerning: 1) booster intention '*If you*

were offered [vaccine type] *as a booster vaccine to maintain protection against COVID-19*

viruses, how likely would you be to accept?' (labels: 'definitely would not accept vaccine' vs.

'definitely would accept vaccine'); 2) perceived booster side effect severity '*Overall, how severe*

do you think the [vaccine type] *side effects are?*' (labels: 'not at all severe' vs. 'extremely

severe'); 3) perceived booster risk '*What do you think the risk to your health would be if you*

received [vaccine type] *as a booster vaccine, bearing in mind its side effects?*' (labels:

'extremely low risk' vs. 'extremely high risk'); 4) booster switch perceptions '*Imagine that*

switching to the [vaccine type] *vaccine was your only option for a booster. Please rate how*

satisfied, happy, and anxious, you would be with this outcome' (labels: 'not at all' vs.

'extremely'). Satisfaction, happiness, and anxiety were rated as sub-items, each yielding a score

of 0 – 100. Where the vaccine type was the same as that previously received by the participant,

wording was changed from 'switching to' to 'continuing with'. Wording of 1 – 3 was adapted

from previous research[39].

Patient Information Leaflets (PILs): Experimental Manipulation

Genuine PILs for the AstraZeneca, Pfizer, and Moderna vaccine were abridged to include

the manufacturer's description of each vaccine, what it is used for, and critically, the possible

side effects resulting from administration. Side effects were retained in their original form and

order. For both the negatively and positively framed PILs, verbal descriptors were in keeping

with those published by the manufacturer (i.e., very common, common, uncommon, rare, very

rare, not known). Wording of assigned frequency bands employed in the negatively framed PILs

was also identical to that of the manufacturer. However, this was inverted in the positively

framed PILs to stress the number of individuals *not* affected (e.g., "Common (90 in 100 or more

people may *not be affected*)"). As multi-modal forms of side effect presentation (e.g., written,

pictorial, verbal) may elicit larger framing effects[16], and numeracy is less likely to moderate the

effect of attribute framing for graphical presentations[59], positive PILs additionally included a

graphical representation of side effect risk to enhance the manipulation. For an example of the

wording used to frame side effects see Figure 2.

Post-Manipulation Measures: COVID-19 Vaccine Perceptions

604   Participants responded to the four vaccine perception items listed above under Baseline

605   Measures (booster intention, booster side effect severity, booster risk, booster acceptance), but

606   only in relation to the vaccine type outlined in the PIL to which they were assigned.

Post-Manipulation Side Effect Perceptions

To determine whether positive framing augments the perception of side effect occurrence

relative to true prevalence rates, fourteen side effects were presented from each PIL. Eleven of

these were associated with concrete prevalence brackets in the original PILs, while the remaining

three were assigned to the 'unknown' category (i.e., could not be estimated at the time of PIL

publication). For each side effect, participants were required to identify the correct verbal

descriptor (very common, common, uncommon, rare, very rare): "*based on the information that*

you read, how common do you think [side effect] is?" (forced-choice answer). They were then

asked, "*In 100,000 people, how many do you think would experience* [side effect] *if they received*

a [framed vaccine name] *booster vaccine?"* (free-response, limited to numbers at up to 10

decimal places). The three 'unknown' side effects were analysed separately to determine the

effect of framing when prevalence rates are not provided.

Statistical Analysis

Statistical analysis was performed using R (version 4.1.1). Statistical analyses were a

combination of ANCOVAs (where baseline measures were available) or ANOVAs, reported

with Type III Sum of Squares. An alpha of .05 was accepted as the threshold for statistical

significance. Sample size (estimated N=1200) was calculated based on an *a priori* power analysis

(95% power, alpha=.05, effect size f^2=0.02) for a separate study run concurrently that contained

more predictor variables (N=9), and therefore required more power, than the study presented

here (further details are contained in the study pre-registration form). An effect size for attribute

framing was additionally derived from previous research (average effect size r= 0.175)[16]. An *a*

priori power analysis based on this effect size required a total of 491 participants, providing

reassurance that the projected sample size for the study above provided ample power to detect an

effect of framing in the present study.

Acknowledgements

Sources of Funding: This research was supported by Australian Research Council grants

DP180102061 and DP200101748. The funding body had no involvement in study design,

analysis, interpretation, writing, or the decision to submit the present article for publication.

Data Availability: The code and raw data necessary to replicate the reported analysis is

available through the Open Science Framework repository (means/SEMs needed to reproduce

the analysis figures are included with the raw data):

https://osf.io/d5cvn/?view_only=500c83d90bb9416796e464108ad2fc41

Author contributions: KB and BC conceived the experimental design. KB was responsible for

collecting and analysing the data. KB wrote the first draft of the article. BC edited and

contributed to the final version.

References
649
1   Andrews, N. *et al.* Vaccine effectiveness and duration of protection of Comirnaty,

Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. Preprint at:

https://www.medrxiv.org/content/10.1101/2021.09.15.21263583v2 (2021).

2   Goldberg, Y. *et al.* Waning immunity of the BNT162b2 vaccine: A nationwide study

from Israel. Preprint at:

https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1(2021).

3   Cele, S. *et al.* SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer

BNT162b2 elicited neutralization and requires ACE2 for infection. Preprint at:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669855.2/ (2021).

4   Basile, K. *et al.* Improved neutralization of the SARS-CoV-2 Omicron variant after

Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. Preprint at:

https://www.biorxiv.org/content/10.1101/2021.12.12.472252v1.abstract (2021).

5   Mahase, E. Covid-19 booster vaccines: What we know and who's doing what. *BMJ* **374**,

n2082 (2021).

6   *All adults to be offered COVID-19 boosters by end of January* (gov.uk, 2021);

https://www.gov.uk/government/news/all-adults-to-be-offered-covid-19-boosters-by-end-

of-january

7   Gardner, B. J. & Kilpatrick, A. M. Third doses of COVID-19 vaccines reduce infection

and transmission of SARS-CoV-2 and could prevent future surges in some populations: a

modeling study. Preprint at:

https://www.medrxiv.org/content/10.1101/2021.10.25.21265500v3 (2021).

8   Ireland, G. *et al.* Serological responses to COVID-19 booster vaccine in England.

Preprint at: https://www.medrxiv.org/content/10.1101/2021.11.22.21266692v1(2021).

9   MacDonald, N. E. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* **33**,

4161-4164 (2015).

10   *Ten threats to global health in 2019* (World Health Organisation, 2019);

https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019

11   Solís Arce, J. S. *et al.* COVID-19 vaccine acceptance and hesitancy in low- and middle-

income countries. *Nature Medicine* **27**, 1385-1394 (2021).

12   *Why won't Americans get vaccinated?* (Economist/YouGov poll, 2021);

https://today.yougov.com/topics/politics/articles-reports/2021/07/15/why-wont-

americans-get-vaccinated-poll-data

13   Rzymski, P., Poniedziałek, B. & Fal, A. Willingness to Receive the Booster COVID-19

Vaccine Dose in Poland. *Vaccines* **9**, 1286 (2021).

14   *World Health Organization. Data for action: achieving high uptake of COVID-19*

vaccines: gathering and using data on the behavioural and social drivers of vaccination:

a guidebook for immunization programmes and implementing partners: interim

guidance, 1 April 2021. (World Health Organization, 2021);

https://apps.who.int/iris/handle/10665/340645

15   Levin, I. P., Schneider, S. L. & Gaeth, G. J. All Frames Are Not Created Equal: A

Typology and Critical Analysis of Framing Effects. *Organizational Behavior and Human*

Decision Processes **76**, 149-188 (1998).

16   Barnes, K. *et al.* Can Positive Framing Reduce Nocebo Side Effects? Current Evidence

and Recommendation for Future Research. *Frontiers in Pharmacology* **10**, 167 (2019).

17   O'Connor, A. M., Pennie, R. A. & Dales, R. E. Framing effects on expectations,

decisions, and side effects experienced: The case of influenza immunization. *Journal of*

Clinical Epidemiology **49**, 1271-1276 (1996).

18   Bigman, C. A., Cappella, J. N. & Hornik, R. C. Effective or ineffective: Attribute framing

and the human papillomavirus (HPV) vaccine. *Patient Education and Counseling* **81**,

S70-S76 (2010).

19   Sudharsanan, N., Favaretti, C., Hachaturyan, V., Bärnighausen, T. & Vandormael, A.

Effects of Side-Effect Risk Framing Strategies on COVID-19 Vaccine Intentions in the

United States and the United Kingdom: A Randomized Controlled Trial. Preprint at:

https://www.medrxiv.org/content/10.1101/2021.10.12.21264877v2 (2021).

20   Chen, T., Dai, M., Xia, S. & Zhou, Y. Do Messages Matter? Investigating the Combined

Effects of Framing, Outcome Uncertainty, and Number Format on COVID-19

Vaccination Attitudes and Intention. *Health Communication*, 1-8 (2021).

21   Huang, Y. & Liu, W. Promoting COVID-19 Vaccination: The Interplay of Message

Framing, Psychological Uncertainty, and Public Agency as a Message Source. *Science*

Communication **44**, 3-29 (2021).

22   Lentzen, M.-P. *et al.* A retrospective analysis of social media posts pertaining to COVID-

19 vaccination side effects. *Vaccine* **40**, 43-51 (2022).

23   Jamison, A. M. *et al.* Vaccine-related advertising in the Facebook Ad Archive. *Vaccine*

38, 512-520 (2020).

24   Ndwandwe, D. & Wiysonge, C. S. COVID-19 vaccines. *Current Opinion in Immunology*

71, 111-116 (2021).

25 Donovan, R. J. & Jalleh, G. Positive versus Negative Framing of a Hypothetical Infant
Immunization: The Influence of Involvement. *Health Education & Behavior* **27**, 82-95
(2000).

26 Benjamin, D., Por, H.-H. & Budescu, D. Climate Change Versus Global Warming: Who
Is Susceptible to the Framing of Climate Change? *Environment and Behavior* **49**, 745-
770 (2016).

27 Haydarov, R. & Gordon, J. C. Effect of combining attribute and goal framing within
messages to change vaccination behavior. *Journal of Communication in Healthcare* **8**,
45-54 (2015).

28 *Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron*
SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine
Composition (TAG-CO-VAC) (World Health Organization, 2022);
https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-19-vaccines-in-
the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-
advisory-group-on-covid-19-vaccine-composition

29 Pfizer plans to manufacture up to 100 million doses of omicron-specific vaccine by
spring (*The Washington Post,* 2022);
https://www.washingtonpost.com/business/2022/01/11/pfizer-omicron-specific-vaccine/

30 Gasteiger, C., Lobo, M., Dalbeth, N. & Petrie, K. J. Patients' beliefs and behaviours are
associated with perceptions of safety and concerns in a hypothetical biosimilar switch.
Rheumatology International **41**, 163-171 (2021).

31 Doyle, S. *et al.* What happens to patients who have their asthma device switched without
their consent? *Prim Care Respir J* **19**, 131-139 (2010).

32 Webster, R. K. & Rubin, G. J. The Effect of Positively Framing Side-Effect Risk in Two
Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A
Randomised Trial of 16- to 75-Year-Olds in England. *Drug Safety* **43**, 1011-1022 (2020).

33 Krishnamurthy, P., Carter, P. & Blair, E. Attribute Framing and Goal Framing Effects in
Health Decisions. *Organizational Behavior and Human Decision Processes* **85**, 382-399
(2001).

34 Levin, I. P., Schnittjer, S. K. & Thee, S. L. Information framing effects in social and
personal decisions. *Journal of Experimental Social Psychology* **24**, 520-529 (1988).

35   Zimmermann, C., Baldo, C. & Molino, A. Framing of outcome and probability of

recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in

hypothetical patient scenarios. *Breast Cancer Research and Treatment* **60**, 9-14 (2000).

36   Marteau, T. M. Framing of information: Its influence upon decisions of doctors and

patients. *British Journal of Social Psychology* **28**, 89-94 (1989).

37   Webster, R. K. & Rubin, G. J. Predicting Expectations of Side-Effects for Those Which

Are Warned Versus Not Warned About in Patient Information Leaflets. *Ann Behav Med*

12, 1253–1261 (2021).

38   Herber, O. R., Gies, V., Schwappach, D., Thürmann, P. & Wilm, S. Patient information

leaflets: informing or frightening? A focus group study exploring patients' emotional

reactions and subsequent behavior towards package leaflets of commonly prescribed

medications in family practices. *BMC Family Practice* **15**, 163 (2014).

39   Berry, D. C., Raynor, D. K. & Knapp, P. Communicating risk of medication side effects:

An empirical evaluation of EU recommended terminology. *Psychology, Health &*

Medicine **8**, 251-263 (2003).

40   *Research and analysis: Coronavirus vaccine - weekly summary of Yellow Card reporting*

(gov.uk, 2021); https://www.gov.uk/government/publications/coronavirus-covid-19-

vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting

41   Myers, J. L. & Well, A. D. *Research design and statistical analysis, 2nd ed*. (Lawrence

Erlbaum Associates Publishers, 2003).

42   Cardinal, R. N. & Aitken, M. R. F. *ANOVA for the behavioural sciences researcher.*

(Lawrence Erlbaum Associates Publishers, 2006).

43   Llewellyn-Thomas, H. A., McGreal, M. J. & Thiel, E. C. Cancer Patients' Decision

Making and Trial-entry Preferences: The Effects of "Framing" Information about Short-

term Toxicity and Long-term Survival. *Medical Decision Making* **15**, 4-12 (1995).

44   Ferguson, E. & Gallagher, L. Message framing with respect to decisions about

vaccination: The roles of frame valence, frame method and perceived risk. *British*

Journal of Psychology **98**, 667-680 (2007).

45   Jasper, J. D., Goel, R., Einarson, A., Gallo, M. & Koren, G. Effects of framing on

teratogenic risk perception in pregnant women. *The Lancet* **358**, 1237-1238 (2001).

46   Webster, R. K., Weinman, J. & Rubin, G. J. Explaining all without causing unnecessary
harm: Is there scope for positively framing medical risk information? *Patient Education*
and Counseling **102**, 602-603 (2019).

47   Freling, T. H., Vincent, L. H. & Henard, D. H. When not to accentuate the positive: Re-
examining valence effects in attribute framing. *Organizational Behavior and Human*
Decision Processes **124**, 95-109 (2014).

48   Dan, V. & Dixon, G. N. Fighting the Infodemic on Two Fronts: Reducing False Beliefs
Without Increasing Polarization. *Science Communication* **43**, 674-682 (2021).

49   Nyhan, B. & Reifler, J. Does correcting myths about the flu vaccine work? An
experimental evaluation of the effects of corrective information. *Vaccine* **33**, 459-464
(2015).

50   Webster, R. K., Weinman, J. & Rubin, G. J. People's Understanding of Verbal Risk
Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to
65-Year-Olds in England. *Drug Safety* **40**, 743-754 (2017).

51   Berry, D. C., Knapp, P. R. & Raynor, T. Is 15 per cent very common? Informing people
about the risks of medication side effects. *International Journal of Pharmacy Practice*
10, 145-151 (2002).

52   Berry, D. C., Raynor, D. K., Knapp, P. & Bersellini, E. Patients' Understanding of Risk
Associated with Medication Use. *Drug Safety* **26**, 1-11 (2003).

53   Knapp, P. *et al.* Communicating the Risk of Side Effects to Patients. *Drug Safety* **32**, 837-
849 (2009).

54   Gerend, M. A. & Shepherd, J. E. Predicting Human Papillomavirus Vaccine Uptake in
Young Adult Women: Comparing the Health Belief Model and Theory of Planned
Behavior. *Annals of Behavioral Medicine* **44**, 171-180 (2012).

55   Lehmann, B. A., Ruiter, R. A. C., Chapman, G. & Kok, G. The intention to get
vaccinated against influenza and actual vaccination uptake of Dutch healthcare personnel.
Vaccine **32**, 6986-6991 (2014).

56   Juraskova, I., Bari, R. A., O'Brien, M. T. & McCaffery, K. J. HPV Vaccine Promotion:
Does Referring to Both Cervical Cancer and Genital Warts Affect Intended and Actual
Vaccination Behavior? *Women's Health Issues* **21**, 71-79 (2011).

57   Jensen, U., Ayers, S. & Koskan, A. *Video-based messages to reduce COVID-19 vaccine*

808   *hesitancy and nudge uptake*. Preprint at: https://psyarxiv.com/df9qw/ (2021).

809   58   Sheeran, P. Intention—Behavior Relations: A Conceptual and Empirical Review.

810   *European Review of Social Psychology* **12**, 1-36 (2002).

811   59   Kreiner, H. & Gamliel, E. Are highly numerate individuals invulnerable to attribute

812   framing bias? Comparing numerically and graphically represented attribute framing.

813   *European Journal of Social Psychology* **47**, 775-782 (2017).

Pre-Screened Participants
(Total N = 1222)

Previous Vaccine:
AstraZeneca
(AZ = 615)

Previous Vaccine:
Pfizer
(Pf = 607)

PIL: Same as Previous Vaccine
(AZ = 205 / Pf = 205)

PIL: Different / Familiar Vaccine
(AZ = 204 / Pf = 200)

PIL: Different / Unfamiliar Vaccine
(AZ = 206 / Pf = 202)

Positive
(AZ = 103 / Pf = 104)

Negative
(AZ = 102 / Pf = 101)

Positive
(AZ = 101 / Pf = 100)

Negative
(AZ = 103 / Pf = 100)

Positive
(AZ = 103 / Pf = 100)

Negative
(AZ = 103 / Pf = 102)

Baseline Primary Outcome:

Baseline Booster Intention

'If you were offered [framed vaccine type] as a booster vaccine to maintain protection against COVID-19 viruses, how likely would you be to accept?' (100-point VAS)

Baseline Secondary Outcomes:

Baseline Perceived Booster Side effect Severity

'Overall, how severe do you think the [framed vaccine type] side effects are?' (100-point VAS)

Baseline Perceived Booster Risk

'What do you think the risk to your health would be if you received [framed vaccine type] as a booster vaccine, bearing in mind its side effects?' (100-point VAS)

Baseline Booster Acceptance

'Imagine that switching to the [framed vaccine type] vaccine was your only option for a booster. Please rate how satisfied, happy, and anxious, you would be with this outcome' (100-point VAS)

Manipulation: Timed presentation of framed PIL information

Post-Manipulation Primary Outcome:

Booster Intention

Post-Manipulation Secondary Outcomes:

Perceived Booster Side effect Severity

Perceived Booster Risk

Booster Acceptance

Post-Manipulation Judgement of Side Effect Prevalence

Assignment of PIL side effects to verbal risk brackets

Forced choice assignment to very common, common, uncommon, rare and very rare categories

Estimation of prevalence (X in every 100,000 individuals)

Estimation of how many people in every 100,000 affected

Negative Attribute Frame (Standard EU Wording)	Positive Attribute Frame	Positive Attribute Frame (Accompanying Infographic)
Common (may affect up to 1 in 10 people)	**Common** (90 in 100 or more people may _**not be affected**_)	**Common:** 90 in 100 (blue circles) or more **not affected**
Uncommon (may affect up to 1 in 100 people)	**Uncommon** (990 in 1,000 or more people may _**not be affected**_)	**Uncommon:** 990 in 1,000 (blue circles) or more **not affected**

3a. Frequency of Participants by Location

Scotland
1st dose 79.1%
2nd dose 71.6%
3rd dose 15.7%

Northern Ireland
1st dose 70.3%
2nd dose 65.8%
3rd dose 6.2%

England
1st dose 74.3%
2nd dose 67.8%
3rd dose 13.3%

Wales
1st dose 77.2%
2nd dose 70.9%
3rd dose 15.8%

Participant Frequency
10   20   30

3b. Demographic Information by Condition

Education by Condition

Other
Post−Graduate
Undergraduate
A−Level
NVQ1/NVQ2
GCSE
Primary/Secondary

Employment by Condition

Unemployed (looking)
Unemployed (not looking)
Student
Self−employed
Retired
Other
Parenting/caring
Part-time
Full-time

Positive Same
Positive Familiar
Positive Unfamiliar
Negative Same
Negative Familiar
Negative Unfamiliar

Age by Condition

Negative Unfamiliar
Negative Familiar
Negative Same
Positive Unfamiliar
Positive Familiar
Positive Same

0   25   50   75   100

Participant Age
25   50   75   100

4a. Booster Intention (Framing*Familiarity)

4b. Booster Intention (Framing*Familiarity*Baseline Intention)

4c. AstraZeneca Vaccine Switches

4d. Pfizer Vaccine Switch

4e. Side Effect Familiarity Ratings

Key: Framing — Negative Frame — Positive Frame

5a. Side Effect Severity (Framing*Baseline Severity)

5b. Perceived Risk (Familiarity*Baseline Risk)

Booster Acceptance

5c. (Framing*Familiarity*Baseline Satisfaction/Happiness)

5d. (Framing*Familiarity*Baseline Anxiety)

6a. Side Effect Category Judgement

6b. Side Effect Frequency Judgement